Viking Therapeutics (VKTX) Accumulated Expenses (2014 - 2018)

Viking Therapeutics has disclosed Accumulated Expenses across 5 years of filings, most recently posting $34000.0 for Q1 2018.

• Accumulated Expenses for Q1 2018 came in at $34000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2018 was $34000.0 (changed N/A YoY), and the FY2017 annual result was $22000.0, down 36.95% from the prior year.
• Accumulated Expenses came in at $34000.0 for Q1 2018 at Viking Therapeutics, up from $22000.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $183611.0 in Q4 2015 to a low of $9982.0 in Q3 2017.
• The 5-year median for Accumulated Expenses is $47113.5 (2016), against an average of $70009.8.
• Across the five-year window, Accumulated Expenses sank 91.37% in 2016 and jumped 467.51% in 2017, its largest moves.
• Viking Therapeutics' Accumulated Expenses stood at $77222.0 in 2014, then soared by 137.77% to $183611.0 in 2015, then tumbled by 81.0% to $34894.0 in 2016, then sank by 36.95% to $22000.0 in 2017, then soared by 54.55% to $34000.0 in 2018.
• The last three Accumulated Expenses figures came in at $34000.0 (Q1 2018), $22000.0 (Q4 2017), and $9982.0 (Q3 2017), per Business Quant data.